...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Emerging microbes & infections. >EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
【24h】

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases

机译：EV-A71疫苗许可证：多价肠病毒疫苗控制手足口病和其他严重疾病的第一步

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Enteroviruses (EVs) are the most common viral agents in humans. Although most infections are mild or asymptomatic, there is a wide spectrum of clinical manifestations that may be caused by EV infections with varying degrees of severity. Among these viruses, EV-A71 and coxsackievirus (CV) CV-A16 from group A EVs attract the most attention because they are responsible for hand, foot and mouth disease (HFMD). Other EV-A viruses such as CV-A6 and CV-A10 were also reported to cause HFMD outbreaks in several countries or regions. Group B EVs such as CV-B3, CV-B5 and echovirus 30 were reported to be the main pathogens responsible for myocarditis and encephalitis epidemics and were also detected in HFMD patients. Vaccines are the best tools to control infectious diseases. In December 2015, China’s Food and Drug Administration approved two inactivated EV-A71 vaccines for preventing severe HFMD.The CV-A16 vaccine and the EV-A71-CV-A16 bivalent vaccine showed substantial efficacy against HFMD in pre-clinical animal models. Previously, research on EV-B group vaccines was mainly focused on CV-B3 vaccine development. Because the HFMD pathogen spectrum has changed, and the threat from EV-B virus-associated severe diseases has gradually increased, it is necessary to develop multivalent HFMD vaccines. This study summarizes the clinical symptoms of diseases caused by EVs, such as HFMD, myocarditis and encephalitis, and the related EV vaccine development progress. In conclusion, developing multivalent EV vaccines should be strongly recommended to prevent HFMD, myocarditis, encephalitis and other severe diseases.
机译：肠病毒（EVs）是人类最常见的病毒制剂。尽管大多数感染是轻度或无症状的，但广泛的临床表现可能是由不同程度的EV感染引起的。在这些病毒中，来自A组EV的EV-A71和柯萨奇病毒（CV）CV-A16引起了最多的关注，因为它们负责手足口病（HFMD）。据报道，其他EV-A病毒（例如CV-A6和CV-A10）在多个国家或地区引起HFMD爆发。据报道，诸如CV-B3，CV-B5和Echovirus 30等B组电动车是造成心肌炎和脑炎流行的主要病原体，在手足口病患者中也被发现。疫苗是控制传染病的最佳工具。 2015年12月，中国食品药品监督管理局批准了两种用于预防严重HFMD的灭活EV-A71疫苗。CV-A16疫苗和EV-A71-CV-A16二价疫苗在临床前动物模型中显示出对HFMD的实质性疗效。以前，对EV-B组疫苗的研究主要集中在CV-B3疫苗的开发上。由于HFMD病原体谱已发生变化，并且与EV-B病毒相关的严重疾病的威胁逐渐增加，因此有必要开发多价HFMD疫苗。这项研究总结了由电动汽车引起的疾病的临床症状，例如手足口病，心肌炎和脑炎，以及相关电动汽车疫苗的开发进展。总之，应强烈建议开发多价EV疫苗，以预防手足口病，心肌炎，脑炎和其他严重疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号